Trump’s end of Medicare Part D subsidy: Potential cost impact

TL/DR –

The U.S. Trump Administration announced the termination of a Medicare subsidy program, known as Part D, which was designed to help lower the cost of prescription drugs for enrollees. The decision was announced by the Centers for Medicare and Medicaid Services (CMS), and it led to widespread discussion online, including claims that it would raise costs for over 11 million Americans. The report stated that around 25% of Part D enrollees would see no change or a decrease in their premiums, around 30% would experience an increase of less than $10, and about 45% would see an increase in the $11 to $20 range per month.


Trump Administration Announces End to Medicare Part D Subsidy Program

An announcement has come from the administration of U.S. President Donald Trump regarding the discontinuation of a Medicare subsidy program, a move that aims to reduce the cost of prescription drugs. The rumors about the Centers for Medicare and Medicaid Services (CMS) planning to withdraw government subsidies for the Medicare program Part D were confirmed to be true. This program was designed to assist enrollees with the cost of their prescribed medications.

Online Discussion and Reaction

News of the proposed policy change sparked discussion and speculation on various social media platforms. Some users claimed that this move would affect the costs for more than 11 million Americans. Other comments claimed that the Trump administration’s decision was an attempt to ‘save money’ by withdrawing support from the most vulnerable sections of American society.

The Official Decision

The agency, CMS, announced the changes as part of its annual release of Medicare’s national average bid amount on July 28. The announcement emphasized the end of the ‘Part D Premium Stabilization Demonstration,’ a program intended to help manage the costs of prescription drugs.

Media Reports Confirm the Announcement

Following the official announcement, major news outlets including The Wall Street Journal, ABC News, Newsweek, and USA Today corroborated the CMS’s announcement. Snopes, a fact-checking website, received a response from the CMS and the White House regarding online posts about the changes made by Mehmet Oz, the administrator of the agency.

Oz’s Official Comment

On July 28, alongside the announcement by the CMS, Oz posted on social media explaining the CMS’s move:

The Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies. This is unacceptable.

We are stabilizing the market so this bailout is no longer needed. Premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums.

Every Medicare beneficiary still has access to low-cost plans, and we will continue to lower prescription drug prices for every American patient, from more MFN deals to our policy giving seniors access to GLP-1s for $50 a month.

Oz further clarified on July 29, in a post, saying: “The Biden administration created a bailout for insurance companies. We ended it.”

Implications of the Change

The termination of this subsidy program could potentially result in increased premiums for Medicare Part D recipients, and push beneficiaries towards Medicare Advantage, the private-insurer version of Medicare, which often includes drug benefits and charges no premiums. According to Juliette Cubanski, Vice President and Director of the Program on Medicare Policy at health policy research nonprofit KFF, these changes are expected to lead to a larger increase in premiums for drug coverage for some Part D enrollees than in recent years.


Read More US Economic News

administrationDonald TrumpMedicareMehmet Ozprescription drugspresident joe bidensubsidy programtrump administration